Memory Pharmaceuticals Corp., of Montvale, N.J., appointed Paul Blake to its board.
MonoGen Inc., of Chicago, named Jan Zorn vice president of regulatory and clinical affairs.
NanoBio Corp., of Ann Arbor, Mich., named Joyce Sutcliffe vice president of research.
NextGen Sciences, of Cambridgeshire, UK, appointed Mike Pisano CEO.
Noven Pharmaceuticals Inc., of Miami, appointed Michael Price vice president and chief financial officer.
Pharmasset Inc., of Princeton, N.J., appointed Michael Rogers chief development officer.
Pieris AG, of Freising-Weihenstephan, Germany, appointed Angelika Stern chief operating officer and promoted Andreas Hohlbaum to chief technology officer.
Sequenom Inc., of San Diego, appointed John Fazio to its board.
SRI International, of Menlo Park, Calif., named Steven Samuelsson director of imaging.
Stem Cell Therapeutics Corp., of Calgary, Alberta, appointed Francesco Bellini to its board.
Sucampo Pharma Ltd., of Tokyo, the Japanese subsidiary of Sucampo Pharmaceuticals, named Kunihiko Soneoka representative director, president and CEO.
Synosia Therapeutics, of San Francisco, appointed Uwe Meye vice president of clinical research and development.
Transdel Pharmaceuticals Inc., of La Jolla, Calif., appointed Anthony Thornley to its board.
Tris Pharma, of Monmouth Junction, N.J., appointed Timothy Saxon vice president of business development.